Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19.

Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain. Therefore, we designed a comprehensive retrospective study encompassing clinical data of 32,864 hospitalized COVID-19 patients, 691 of whom were cancer patients treated with azvudine and 200 were cancer patients treated with Paxlovid. After 2:1 propensity score matching, 397 patients in the azvudine group and 199 patients in the Paxlovid group were enrolled. Cox regression analysis revealed the risk of all-cause death (HR: 1.84, 95% CI: 1.059-3.182, P = 0.030) and composite disease progression (HR: 1.70, 95% CI: 1.043-2.757, P = 0.033) were greater in the Paxlovid group than in the azvudine group. Two sensitivity analyses confirmed the robustness of our findings. The safety analysis of adverse events revealed no statistically significant differences between the two groups. In conclusion, we carried out the first analysis to compare the efficacy and safety of azvudine and Paxlovid in cancer patients with COVID-19 and demonstrated that azvudine significantly reduced the risk of all-cause death and composite disease progression among cancer patients with COVID-19 compared with Paxlovid.